Tag : PLASMA ASSAY

Alzheimer’s disease (AD) is the leading cause of dementia with a growing prevalence worldwide. However, diagnosing and treating AD remains challenging due to the complexity of its pathophysiology. Recently, the National Institute on Aging and the Alzheimer's Association (NIA-AA) updated the 2018 framework for diagnosing and evaluating AD, revising the criteria to incorporate recent advancements in biomarkers. These updated criteria build on the fundamental principle that AD is defined biologically by distinct neuropathologic changes, rather than solely by syndromic presentation, enabling diagnosis through biomarkers. These biomarker-focused criteria thus serve as a bridge between research and clinical practice, offering general principles to guide the diagnosis and staging of AD in line with current scientific understanding.